Sterling Capital Management
LBRX icon

Sterling Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Sterling Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.1K Buy
575
+301
+110% +$12.4K ﹤0.01% 2147
2026
Q2 		$8.89K Sell
274
-94
-26% -$2.76K ﹤0.01% 2287
2026
Q1 		$9.08K Sell
368
-224
-38% -$5.17K ﹤0.01% 2422
2025
Q4 		$13.2K Buy
+592
New +$10.3K ﹤0.01% 2469

Other funds holding LBRX

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Sterling Capital Management's LBRX Position: Q3 2026 in Review

Sterling Capital Management increased its LB Pharmaceuticals (LBRX) stake by 110% in Q3 2026, buying an estimated $12.4K and bringing the position to 575 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Sterling Capital Management first reported a position in LBRX in Q4 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

  • Sterling Capital Management held 575 shares of LB Pharmaceuticals worth $22.1K as of Q3 2026.
  • Sterling Capital Management bought 301 LB Pharmaceuticals shares in Q3 2026, an estimated $12.4K.
  • LB Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2147 holding.
  • Sterling Capital Management first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.